Drug intelligence / Profile preview

lzm012

Development stage: Phase 3
Lead developer: Livzon Monoclonal Antibody
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

LZM012 is a recombinant humanized monoclonal antibody that targets and inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). Developed by Livzon Pharmaceutical, it is designed for the treatment of moderate to severe chronic plaque psoriasis and other immunological disorders. By neutralizing IL-17A and IL-17F, key cytokines involved in inflammatory pathways, LZM012 reduces inflammation associated with autoimmune skin diseases. The drug is currently in phase III clinical trials for psoriasis and phase II for broader immunological disorders[2][5][6].

Other names: LZM 012LZM012LZM-012

Targets

IL17F (Interleukin 17F)IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on lzm012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lzm012.

Explore the full profile